Patents by Inventor Robert O. Dillman

Robert O. Dillman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AUTOLOGOUS DENDRITIC CELL VACCINE KIT AND USES
    Publication number: 20230210982
    Abstract: Disclosed herein is a kit to produce a personalized vaccine based on autologous dendritic cells. The kit contains all the materials, reagents and information necessary to produce a dose of live dendritic cell vaccine against a pathogen organism, part of a pathogen organism, a toxin, a venom, a structure obtained by recombinant method or chemical synthesis.
    Type: Application
    Filed: December 2, 2022
    Publication date: July 6, 2023
    Inventors: Gabriel NISTOR, Hans KIERSTEAD, Robert O. DILLMAN
  • Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells
    Publication number: 20220347277
    Abstract: The present specification provides methods for augmenting the antigenic content, especially of tumor-associated antigens (TAA), and immunogenicity of cancer cells; methods for enhancing cross-presentation in dendritic cells, compositions comprising such manipulated cells derived from single cancer patients; and methods of using those compositions as a personal immunotherapeutic product to treat the donor patient's cancer.
    Type: Application
    Filed: March 18, 2022
    Publication date: November 3, 2022
    Inventors: Gabriel NISTOR, Andrew N. CORNFORTH, Robert O. DILLMAN
  • SOLUBLE PROGRAMMED CELL DEATH PROTEIN-1 AS A BIOMARKER IN CANCER PATIENTS
    Publication number: 20220268775
    Abstract: Disclosed herein are methods for selecting cancer patients for autologous cancer vaccine therapy and methods for predicting survival of cancer patients after autologous cancer vaccine therapy comprising, measuring the level of soluble programmed cell death protein-1 (sPD-1) in the blood of the patient.
    Type: Application
    Filed: July 31, 2020
    Publication date: August 25, 2022
    Inventors: Robert O. Dillman, Gabriel Nistor
  • Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells
    Publication number: 20200230219
    Abstract: The present specification provides methods for augmenting the antigenic content, especially of tumor-associated antigens (TAA), and immunogenicity of cancer cells; methods for enhancing cross-presentation in dendritic cells, compositions comprising such manipulated cells derived from single cancer patients; and methods of using those compositions as a personal immunotherapeutic product to treat the donor patient's cancer.
    Type: Application
    Filed: February 16, 2018
    Publication date: July 23, 2020
    Inventors: Gabriel Nistor, Andrew N. Cornforth, Robert O. Dillman
  • Non-covalent antibody-anthracycline immunocomplexes
    Patent number: 5004606
    Abstract: A composition comprising a non-covalent immunocomplex of an anthracycline agent and an antibody selected to bind a target antigen and enhance the cytotoxicity of the anthracycline agent is disclosed. In accordance with the invention, the efficacy of an anthracycline as an anti-tumor agent for use in in vivo therapy is enhanced by administering to a patient a non-covalent immunocomplex provided herein.
    Type: Grant
    Filed: September 24, 1986
    Date of Patent: April 2, 1991
    Assignee: Hybritech Incorporated
    Inventors: James M. Frincke, Richard M. Bartholomew, Robert O. Dillman